Pregnant women with autoimmune rheumatic diseases (ARDs) and antiphospholipid syndrome (APS) face significantly increased risks of cardiovascular events (CVEs). This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.
Dr. John Cush RheumNow
2 years 8 months ago
The ARGO Project for Rheumatology Fellows
Dr. Sheila Reyes (Philippines) talks with Dr. Lisa Traboco about abstract 2078, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/RRjc38JpEQ https://t.co/q9rCxbWzNh
Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. A EULAR task force set out to develop recommendations for the management of fatigue in people with I-RMDs.
Dr. John Cush RheumNow
2 years 8 months ago
When should we be starting therapy in GCA and PMR?
The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy.
https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM
Dr. John Cush RheumNow
2 years 8 months ago
Save the date for RheumNow Live 2024, on January 27-28, in Dallas, TX, or from the comfort of your own space through our virtual platform!
Why choose RheumNow Live? Because this isn't just another conference – it's a revolution in medical education!
https://t.co/K2YYqjjs8F https://t.co/MinRm9N9rz
Dr. John Cush RheumNow
2 years 8 months ago
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/7GvzttR9HZ https://t.co/wYGiMg4zqK
Dr. John Cush RheumNow
2 years 8 months ago
Promising Therapies for Sjogren's
Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8iSDMKtKwa https://t.co/QCYTnpYKFN
Dr. John Cush RheumNow
2 years 8 months ago
ICYMI: SpA Sleuths: The Case of Undiagnosed IBD
As rheumatologists, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions
https://t.co/dE0NLXKDvT https://t.co/DalUXRf3MB
Dr. John Cush RheumNow
2 years 8 months ago
CBT or Naltrexone in Fibromyalgia
https://t.co/9SGRbY97oD https://t.co/wN2cMuqgHa
Dr. John Cush RheumNow
2 years 8 months ago
Expert consensus(ASAS) prefers SpondyloArthritis(axSpA) as preferred over "ankylosing spondylitis" (historic but no longer appropriate based on MRI research showing this is more than SI disease). AS radiographic axSpA(r-axSpA) can be used interchangeably https://t.co/jvT3lQFaPq https://t.co/WRNrbfjK1S
Dr. John Cush RheumNow
2 years 8 months ago
Danish study compared 106K adults w/ major osteoporotic fracture (hip, vertebrae, wrist, humerus) vs 1+ mill controls & found Mortality highest 30d following 1st index hip Fx (HR 10.98 women; & HR 16.40 men). Pneumonia most common cause of mortality https://t.co/0D7ynN4f5L https://t.co/qX61cgq1SL
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.
